group XIIA sPLA₂ Antibodies

Santa Cruz Biotechnology delivers a wide array of group XIIA sPLA₂ monoclonal antibodies for advanced research in lipid metabolism and inflammatory processes. Group XIIA sPLA₂ monoclonal antibodies demonstrate high performance in western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). Group XIIA secreted phospholipase A₂ (sPLA₂) plays a crucial role in the hydrolysis of phospholipids, leading to the release of fatty acids and lysolipids, which are important mediators in inflammation and cell signaling. The enzyme is implicated in various physiological and pathological processes, including immune responses, cardiovascular diseases, and neurodegenerative disorders. Understanding group XIIA sPLA₂ function is essential for developing therapeutic strategies targeting inflammatory diseases. Researchers worldwide rely on group XIIA sPLA₂ monoclonal antibodies to advance their studies in cellular pathways and disease mechanisms. Group XIIA sPLA₂ monoclonal antibodies enable precise detection and analysis of enzyme activity in diverse experimental settings. Santa Cruz Biotechnology monoclonal antibodies for group XIIA sPLA₂ support researchers in their mission to unlock new insights into inflammatory diseases and potential therapeutic approaches.